Management Team

Kurt Kessler
CEO

THE COMMERCIAL LEADER SUPPORTING THE SCIENCE

PhD in Applied Statistics with 30 years of global pharmaceutical experience

Maria Waldhoer, CSO

Maria Waldhoer
CSO

SCIENCE MOM

PhD with a twenty years track record in GPCR signaling with extensive experience in academia & industry.

Aurélien Rizk, CTO

Aurélien Rizk
CTO

THE HUMAN BEHIND THE MODELS

PhD in computer science with 10 years of experience in systems biology.

Luca Zenone

Luca Zenone
CFO/COO

ENSURING THE CLOCK KEEPS TICKING

MSc in Business Administration running all the finance, legal and operations of the company.

Board of Directors

Prof. Dr. Jens Gobrecht

Prof. Dr. Jens Gobrecht

HEAD OF BOARD OF DIRECTORS

Prof. emeritus Laboratory for Micro- and Nanotechnology at the Paul Scherrer Institute (PSI); Co-founder of EULITHA AG; Honorary Member of the Swiss Nanoscience Institute

Dr. Aurélien Rizk

Dr. Aurélien Rizk

BOARD MEMBER

PhD Computer Science; Co-Founder and CTO InterAx Biotech; Co-Founder Algorizk
Luca Zenone

Luca Zenone

Luca Zenone

BOARD MEMBER

MSc ETH Management, Technology and Economics; Engineering and Management Consulting; Co-Founder, CFO and COO InterAx Biotech

Dr. Yiannis Monovoukas

Dr. Yiannis Monovoukas

BOARD MEMBER

Managing Partner, Falcon III and SpringTide Ventures Fund I; CEO, Helios Cardiovascular and AuraGen Aesthetics

Dr. Bettina Ernst

Dr. Bettina Ernst

BOARD MEMBER

CEO of PRECLIN Biosystems;Board member of multiple biotech companies;VP of Board of Swiss Biotech Association

Scientific Advisors

Prof. Gebhard Schertler

Prof. Gebhard Schertler

Prof. Gebhard Schertler

HEAD OF SCIENTIFIC ADVISORY BOARD

Professor for Structural Biology ETH Zürich; Head of Biology and Chemistry at the Paul Scherrer Institute (PSI)
Martha Sommer InterAx

Dr. Martha Sommer

Dr. Martha Sommer

SCIENTIFIC ADVISOR

Institute for Medical Physics and Biophysics at the Charité Berlin; Founder of the European Research Network on Signal Transduction (ERNEST)
Prof. Michel Bouvie

Prof. Michel Bouvier

Prof. Michel Bouvier

SCIENTIFIC ADVISOR

Professor for Biochemistry Université de Montréal; CEO Institute for Research in Immunology and Cancer (IRICoR), Montreal

Dr. Philipp Berger

Dr. Philipp Berger

SCIENTIFIC ADVISOR

Senior Scientist, Paul Scherrer Institute (PSI)
Dr. Chris de Graaf

Dr. Chris de Graaf

Dr. Chris de Graaf

SCIENTIFIC ADVISOR

Director of Computational Chemistry, Heptares Therapeutics
Prof. Jennifer L. Whistler

Prof. Jennifer L. Whistler

Prof. Jennifer L. Whistler

SCIENTIFIC ADVISOR

Professor at the University of California, Davis; Associate Director at Center for Neuroscience

With Support From

Our Story

2010
2010
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx

2011
During his PostDoc at the Paul Scherrer Institute, Aurélien Rizk plants the “Systems Biology” seed of InterAx

2014

2014
After his MSc in Management Technology and Economics, Luca Zenone plants the “Business” seed of InterAx

August 2014
The project receives 150k CHF from the ETH Foundation

December 2014
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
2015

December 2015
Martin Ostermaier, Aurélien Rizk, Luca Zenone and the Paul Scherrer Institute are awarded a 3-year technology development grant from the Swiss Commission for Technology and Innovation towards the creation of InterAx

2016
January 2016
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech

April 2016
Martin Ostermaier, Luca Zenone, Aurélien Rizk, Gebhard Schertler and Philipp Berger co-found InterAx Biotech AG

December 2016
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
2017

February 2017
Maria Waldhoer joins InterAx as Chief Scientific Officer

December 2017
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
2019

January 2019
InterAx closes a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere

April 2019
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.

Now
For most recent developments, see News page

Our Story

2010
2010
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx

2011
During his PostDoc at the Paul Scherrer Institute, Aurélien Rizk plants the “Systems Biology” seed of InterAx

2014

2014
After his MSc in Management Technology and Economics, Luca Zenone plants the “Business” seed of InterAx

August 2014
The project receives 150k CHF from the ETH Foundation

December 2014
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
2015

December 2015
Martin Ostermaier, Aurélien Rizk, Luca Zenone and the Paul Scherrer Institute are awarded a 3-year technology development grant from the Swiss Commission for Technology and Innovation towards the creation of InterAx Biotech

2016
January 2016
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech

April 2016
InterAx Biotech AG is being incorporated

December 2016
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
2017

February 2017
Maria Waldhoer joins InterAx as Chief Scientific Officer

December 2017
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
2019

January 2019
InterAx closes a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere

April 2019
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.

Now
For most recent developments, see News page